CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...